Fulcrum Therapeutics/$FULC

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Fulcrum Therapeutics

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Ticker

$FULC
Sector
Primary listing

Employees

45

FULC Metrics

BasicAdvanced
$379M
-
-$1.18
2.38
-

What the Analysts think about FULC

Analyst ratings (Buy, Hold, Sell) for Fulcrum Therapeutics stock.

Bulls say / Bears say

The 12 mg cohort of the Phase 1b PIONEER trial produced strong, clinically meaningful outcomes, including an absolute mean increase of 8.6% in fetal hemoglobin, 67% pan-cellular F-cell induction, a mean rise of 0.9 g/dL in hemoglobin, promising trends toward reduced VOC, and no treatment-related serious adverse events over 12 weeks.
As of Q2 2025, Fulcrum had $214.1 million in cash, cash equivalents, and marketable securities, giving it funding runway into 2028 to support clinical programs and discovery research.
R&D expenses fell to $13.0 million and G&A expenses to $6.8 million in Q2 2025 due to workforce reductions and program discontinuations, boosting operational efficiency and prolonging the company's financial runway.
Pipeline risk is elevated because Fulcrum's main program depends on the forthcoming 20 mg cohort data from the Phase 1b PIONEER trial, which is due by year-end and represents a critical value inflection point.
Fulcrum posted a net loss of $17.3 million for Q2 2025, compared to net income of $55.4 million in Q2 2024, highlighting ongoing operating losses without product revenue.
Collaboration revenue dropped to zero in Q2 2025 from $80 million in the previous year, eliminating a significant non-dilutive funding source and increasing the need to tightly manage cash burn.
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2025.

FULC Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

FULC Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $FULC

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs